CARACTERIZACIÓN DE BACILOS GRAM NEGATIVOS PRODUCTORES DE CARBAPENEMASAS EN AISLADOS CLÍNICOS DEL HOSPITAL REGIONAL DE VILLARRICA, 2023-2024
DOI:
https://doi.org/10.64668/rccss.v2i2114133Keywords:
Carbapenem-resistant Enterobacteriaceae, Enterobacteriaceae infections, antimicrobial drug resistance, multiple drug resistance bacterial, infection controlAbstract
Objective: To determine the frequency of isolation of Carbapenemase-Producing Gram-Negative Bacilli (CP-GNB) in biological samples from patients hospitalized in the different services of the Villarrica Regional Hospital, during the 2023-2024 period. Methodology: A quantitative, observational, descriptive, retrospective study was conducted on 44 adult patients who had been hospitalized in the Villarrica Regional Hospital and whose biological samples confirmed the isolation of Carbapenemase-Producing Gram-Negative Bacilli. Incomplete clinical records or those with clinical suspicion without microbiological confirmation were excluded. Prior authorization was requested from Directors and Service Chiefs to access the patients' clinical and microbiological records. A pre-structured form was used to record the studied variables: age, sex, origin, service, diagnosis, type of biological sample, isolated multi-drug resistant microorganism, type of carbapenemase, length of hospital stay, and condition at discharge. Results: The services most affected were Internal Medicine and the Intensive Care Unit (ICU) (39%). Urinary tract infections and pneumonia were the most frequent diagnoses. Regarding biological samples, rectal swab was the most common type (80%). Microbiological analysis revealed that Klebsiella pneumoniae was the predominant pathogen, isolated in 68% of cases, followed by Escherichia coli and Enterobacter cloacae complex (9%).Conclusion: Class B carbapenemases, or metallo-beta-lactamases (MBLs), were primarily identified in 86% of cases, while the remaining 14% corresponded to Class A carbapenemases.
References
1. Dandachi I, Chaddad A, Hanna J, Matta J, Daoud Z. Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach. Front Microbiol. 2019 Aug 23;10: 1941. Disponible en: doi: 10.3389/fmicb.2019.01941.
2. Alemayehu T, Asnake S, Tadesse B, Azerefegn E, Mitiku E, Agegnehu A, Nigussie N, H/Mariam T, Desta M. Phenotypic Detection of Carbapenem-Resistant Gram-Negative Bacilli from a Clinical Specimen in Sidama, Ethiopia: A Cross-Sectional Study. Infect Drug Resist. 2021 Feb 2; 14:369-380. Disponible en: doi: 10.2147/IDR.S289763.
3. Elbadawi HS, Elhag KM, Mahgoub E, Altayb HN, Ntoumi F, Elton L, McHugh TD, Tembo J, Ippolito G, Osman AY, Zumla A, Hamid MMA. Detection and characterization of carbapenem resistant Gram-negative bacilli isolates recovered from hospitalized patients at Soba University Hospital, Sudan. BMC Microbiol. 2021 May 4;21(1):136. Disponible en: doi: 10.1186/s12866-021-02133-1.
4. Naim H, Rizvi M, Gupta R, Azam M, Taneja N, Shukla I, Khan HM. Drug Resistance and Molecular Epidemiology of Carbapenem Resistant Gram-negative Bacilli Isolates. J Glob Infect Dis. 2018 Jul-Sep;10(3):133-139. Disponible en: doi: 10.4103/jgid.jgid_74_17.
5. Hegazy EE, Bahey MG, Abo Hagar AM, Elkholy AA, Mohamed EA. Carbapenem-Resistant Gram-Negative Bacilli Causing Ventilator Associated Pneumonia: Study of MASTDISCS Combi Carba Plus for Detection of Carbapenemase Producing Enterobacterales. Infect Drug Resist. 2022 Oct 31; 15:6331-6342. Disponible en: doi: 10.2147/IDR.S385294.
6. Nieto-Saucedo JR, López-Jacome LE, Franco-Cendejas R, Colín-Castro CA, Hernández-Duran M, Rivera-Garay LR, Zamarripa-Martinez KS, Mosqueda-Gómez JL. Carbapenem-Resistant Gram-Negative Bacilli Characterization in a Tertiary Care Center from El Bajio, Mexico. Antibiotics (Basel). 2023 Aug 8;12(8):1295. Disponible en: doi: 10.3390/antibiotics12081295.
7. Haji SH, Aka STH, Ali FA. Prevalence and characterisation of carbapenemase encoding genes in multidrug-resistant Gram-negative bacilli. PLoS One. 2021 Nov 1;16(11):e0259005. Disponible en: doi: 10.1371/journal.pone.0259005.
8. Exner M, Bhattacharya S, Christiansen B, Gebel J, Goroncy-Bermes P, Hartemann P, Heeg P, Ilschner C, Kramer A, Larson E, Merkens W, Mielke M, Oltmanns P, Ross B, Rotter M, Schmithausen RM, Sonntag HG, Trautmann M. Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria? GMS Hyg Infect Control. 2017 Apr 10;12: Doc05. Disponible en: doi: 10.3205/dgkh000290.
9. Hansen GT. Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria. Infect Dis Ther. 2021 Mar;10(1):75-92. Disponible en: doi: 10.1007/s40121-020-00395-2.
10. Bassetti M, Garau J. Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections. J Antimicrob Chemother. 2021 Nov 22;76(Suppl 4): iv23-iv37. Disponible en: doi: 10.1093/jac/dkab352.
11. Melgarejo-Touchet Nancy, Brítez Cristina Mariel, Busignani Sofía, Falcón Miryan, López Evelyn, Laconich Marcela et al. Caracterización molecular de carbapenemasas en bacilos gramnegativos circulantes en hospitales de Paraguay. Primer cuatrimestre 2021. Mem. Inst. Investig. Cienc. Salud 2021 Aug; 19(2): 49-58. Disponible en: https://doi.org/10.18004/mem.iics/1812-9528/2021.019.02.49
12. Hopman J, Meijer C, Kenters N, Coolen JPM, Ghamati MR, Mehtar S, van Crevel R, Morshuis WJ, Verhagen AFTM, van den Heuvel MM, Voss A, Wertheim HFL. Risk Assessment After a Severe Hospital-Acquired Infection Associated With Carbapenemase-Producing Pseudomonas aeruginosa. JAMA Netw Open. 2019 Feb 1;2(2): e187665. Disponible en: doi: 10.1001/jamanetworkopen.2018.7665.
13. Noël A, Huang TD, Berhin C, Hoebeke M, Bouchahrouf W, Yunus S, Bogaerts P, Glupczynski Y. Comparative Evaluation of Four Phenotypic Tests for Detection of Carbapenemase-Producing Gram-Negative Bacteria. J Clin Microbiol. 2017 Feb;55(2):510-518. Disponible en: doi: 10.1128/JCM.01853-16.
14. Yin L, Wu N, Yan G, Lu L, Qian H, Yang W, Ma J, He L, Lu G, Zhai X, Wang C. Carbapenem-resistant gram-negative bacterial prevention practice in nosocomial infection and molecular epidemiological characteristics in a pediatric intensive care unit. Heliyon. 2023 Aug 6;9(8): e18969. Disponible en: doi: 10.1016/j.heliyon.2023.e18969.
15. Giacobbe DR, Ciacco E, Girmenia C, Pea F, Rossolini GM, Sotgiu G, Tascini C, Tumbarello M, Viale P, Bassetti M; ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy). Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. Infect Drug Resist. 2020 Dec 29; 13:4697-4711. Disponible en: doi: 10.2147/IDR.S205309.
16. Jean SS, Harnod D, Hsueh PR. Global Threat of Carbapenem-Resistant Gram-Negative Bacteria. Front Cell Infect Microbiol. 2022 Mar 15;12:823684. Disponible en: doi: 10.3389/fcimb.2022.823684.
17. Shein AMS, Wannigama DL, Higgins PG, Hurst C, Abe S, Hongsing P, Chantaravisoot N, et al. High prevalence of mgrB-mediated colistin resistance among carbapenem-resistant Klebsiella pneumoniae is associated with biofilm formation, and can be overcome by colistin-EDTA combination therapy. Sci Rep. 2022 Jul 28;12(1):12939. Disponible en: doi: 10.1038/s41598-022-17083-5.
18. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022 Aug 25;75(2):187-212. Disponible en: doi: 10.1093/cid/ciac268. PMID: 35439291;
19. Heidari R, Farajzadeh Sheikh A, Hashemzadeh M, Farshadzadeh Z, Salmanzadeh S, Saki M. Antibiotic resistance, biofilm production ability and genetic diversity of carbapenem-resistant Pseudomonas aeruginosa strains isolated from nosocomial infections in southwestern Iran. Mol Biol Rep. 2022 May;49(5):3811-3822. Disponible en: doi: 10.1007/s11033-022-07225-3.
20. Debabza M, Dziri R, Mechai A, Bouguessa A, Klibi N, Ouzari HI. Characterization of carbapenemase-producing Gram-negative bacilli: first report of blaNDM-1 in Enterobacter cloacae. J Infect Dev Ctries. 2023 Sep 30;17(9):1300-1309. Disponible en: doi: 10.3855/jidc.18031.
21. Kanj SS, Bassetti M, Kiratisin P, Rodrigues C, Villegas MV, Yu Y, van Duin D. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2022 Sep; 60(3):106633. Disponible en: doi: 10.1016/j.ijantimicag.2022.106633.
22. Cruz-López F, Martínez-Meléndez A, Morfin-Otero R, Rodriguez-Noriega E, Maldonado-Garza HJ, Garza-González E. Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens. Front Cell Infect Microbiol. 2022 May 20;12:884365. Disponible en: doi: 10.3389/fcimb.2022.884365.
23. Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, et at. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Clin Infect Dis. 2021 Nov 2;73(9):1664-1676. Disponible en: doi: 10.1093/cid/ciab176.
24. Cruz-López F, Martínez-Meléndez A, Villarreal-Treviño L, Morfín-Otero R, Maldonado-Garza H, Garza-González E. Contamination of healthcare environment by carbapenem-resistant Acinetobacter baumannii. Am J Med Sci. 2022 Dec;364(6):685-694. Disponible en: doi: 10.1016/j.amjms.2022.07.003.
25. Falgenhauer L, Nordmann P, Imirzalioglu C, Yao Y, Falgenhauer J, Hauri AM, Heinmüller P, Chakraborty T. Cross-border emergence of clonal lineages of ST38 Escherichia coli producing the OXA-48-like carbapenemase OXA-244 in Germany and Switzerland. Int J Antimicrob Agents. 2020 Dec;56(6):106157. Disponible en: doi: 10.1016/j.ijantimicag.2020.106157.
26. Spadar A, Perdigão J, Campino S, Clark TG. Large-scale genomic analysis of global Klebsiella pneumoniae plasmids reveals multiple simultaneous clusters of carbapenem-resistant hypervirulent strains. Genome Med. 2023 Jan 19;15(1):3. Disponible en: doi: 10.1186/s13073-023-01153-y.
27. Cruz-López F, Martínez-Meléndez A, Villarreal-Treviño L, Morfín-Otero R, Maldonado-Garza H, Garza-González E. Contamination of healthcare environment by carbapenem-resistant Acinetobacter baumannii. Am J Med Sci. 2022 Dec;364(6):685-694. Disponible en: doi: 10.1016/j.amjms.2022.07.003.
28. Dropa M, Daoud Z. Editorial: The global threat of carbapenem-resistant gram-negative bacteria. Front Cell Infect Microbiol. 2022 Aug 1;12:974268. Disponible en: doi: 10.3389/fcimb.2022.974268.
29. Gandra S, Choi J, McElvania E, Green SJ, Harazin M, Thomson RB, Dantas G, Singh KS, Das S. Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coli. Int J Antimicrob Agents. 2020 Mar;55(3):105902. Disponible en: doi: 10.1016/j.ijantimicag.2020.105902.
30. Canton R, Doi Y, Simner PJ. Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol. Expert Rev Anti Infect Ther. 2022 Aug;20(8):1077-1094. Disponible en: doi: 10.1080/14787210.2022.2071701
31. Tenover FC, Nicolau DP, Gill CM. Carbapenemase-producing Pseudomonas aeruginosa -an emerging challenge. Emerg Microbes Infect. 2022 Dec;11(1):811-814. Disponible en: doi: 10.1080/22221751.2022.2048972.
32. Lerner AO, Abu-Hanna J, Carmeli Y, Schechner V. Environmental contamination by carbapenem-resistant Acinetobacter baumannii: The effects of room type and cleaning methods. Infect Control Hosp Epidemiol. 2020 Feb;41(2):166-171. Disponible en: doi: 10.1017/ice.2019.307. 33.
33. Han R, Shi Q, Wu S, Yin D, Peng M, Dong D, Zheng Y, Guo Y, Zhang R, Hu F; China Antimicrobial Surveillance Network (CHINET) Study Group. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. Front Cell Infect Microbiol. 2020 Jul 3;10:314. Disponible en: doi: 10.3389/fcimb.2020.00314
